Etizolam Stats & Data

Etizolam is prescribed in Japan and India under brand names like Depas, Pasaden, Etilaam, Etizola, and Etizest, but is unapproved in many other countries; in unregulated markets it often appears as pressed tablets or powders of uncertain dose. Counterfeit 'benzo' tablets and blister packs may contain etizolam or other designer benzodiazepines; use drug checking services when possible and do not assume branding equals content. Compared dose-for-dose, 1 mg etizolam is commonly estimated around 10 mg diazepam in anxiolytic/sedative effect; individual response varies, so start low to avoid blackouts. Onset is relatively fast (roughly 10–40 minutes), and redosing during the come-up markedly increases the risk of amnesia, disinhibition, accidents, and respiratory depression, especially if other depressants are onboard. As a CYP3A4 substrate, etizolam’s levels can be increased by potent CYP3A4 inhibitors (e.g., some azole antifungals, macrolide antibiotics, fluvoxamine) and reduced by inducers (e.g., carbamazepine); this can unpredictably strengthen or weaken effects. Mixing with opioids, alcohol, GHB/GBL, or Z‑drugs greatly raises overdose risk (compounded sedation, hypoventilation, aspiration); avoid concurrent use and seek help immediately if someone cannot be roused or breathes slowly or irregularly. In several drug checking datasets, benzo-adulterants, including etizolam, appear in expected-fentanyl samples—be vigilant if using opioids, as combined depressants drive severe poisonings. Withdrawal after sustained or high-dose use can produce severe rebound anxiety, insomnia, tremor, and seizures; never abruptly stop after regular use—medical supervision and gradual tapering are strongly advised. Driving or operating machinery is unsafe while under the influence and can remain unsafe the next morning because of residual sedation and psychomotor impairment. Volumetric dosing (diluting a known small mass into a measured volume) reduces dosing error with powders/solutions; avoid eyeballing or 'drops' from unknown-concentration liquids. Intranasal and especially injection routes are discouraged due to poor solubility, binders, infection risk, and unpredictable kinetics—oral or sublingual are the least risky non-medical routes. Packaging and appearance are unreliable indicators of content; use reagent tests and, where available, GC/MS drug checking to verify. Store powders/solutions cool, dry, and protected from light to limit degradation, and keep all benzodiazepines secured to prevent accidental pediatric/naïve exposure.